-- 週五,受伊朗宣布霍爾木茲海峽開放後原油價格暴跌的影響,主要生物燃料原料期貨價格下跌。 芝加哥期貨交易所5月大豆油期貨合約早盤下跌1.27%,至每磅68.45美分;5月大豆期貨合約下跌0.45%,至每蒲式耳11.58美元。 儘管化石燃料價格走弱可能導致生質燃料需求下降,但美國國內消費成長的跡象可能會支撐大豆價格,尤其是在3月份大豆壓榨量強勁的情況下。 根據道瓊斯報道,Stone X表示,美國市場正受到國內壓榨量和大豆油需求的重塑,並正在減少對出口市場的依賴。 然而,ADM投資者服務公司的馬克索德伯格表示,市場參與者仍將逐步把注意力轉向川普-習近平峰會,等待中國增購的跡象。 週四,美國農業部報告稱,截至4月9日當週,大豆出口銷量跌至本銷售年度新低,僅910萬蒲式耳。本季大豆出口承諾總量已達14億蒲式耳,較2025年同期水準低18%。 同時,路透社引述巴西農業組織Abiove的數據,預計巴西全年大豆出口量將達到創紀錄的1.136億噸,顯示市場供應充足。 在亞洲,受原油和豆油價格走低的影響,馬來西亞棕櫚油期貨週五下跌,連續第二週收跌。出口疲軟令市場情緒承壓。 馬來西亞衍生性商品交易所5月原棕櫚油合約下跌1.28%,至每噸4,386馬來西亞林吉特(1,108.84美元);6月合約小幅下跌1.21%,至每噸4,422林吉特。受原油價格回落的影響,兩份合約本週累計下跌約2.5%,前一週已下跌6%。 能源價格走低可能會降低生質燃料的競爭力,而此時主要棕櫚油生產國正準備提高生質柴油的摻混比例。 作為全球最大的棕櫚油生產國,印尼計劃在下半年將生質柴油的摻混比例從目前的40%提高到50%(B50),此舉可能會減少出口供應。 第二大棕櫚油生產國馬來西亞目前正在實施B10項目,預計很快將開始推廣B12,並計劃稍後升級至B15。 第三大棕櫚油生產國泰國剛開始推出B7項目,先前為B5。 中東衝突嚴重影響了柴油供應,促使東南亞棕櫚油生產商提高生物柴油摻混比例,以滿足國內市場需求。 馬來西亞的出口市場預計將增強競爭力,進而可能提振出貨量。由於價格高企,其4月前15天的出口量較3月同期下降了34%。 根據《馬來西亞邊緣報》(The Edge Malaysia)引述CGS國際公司的報道,主要進口國印度和中國可能會在市場穩定後推遲採購。 根據新聞社引述種植園和商品部長塞里·諾萊尼·艾哈邁德的話稱,儘管如此,印度可能仍會因為棕櫚油的成本競爭力而優先選擇棕櫚油而非其他植物油。 Trading Economics表示,在3月進口量降至三個月低點後,印度可能還會在季節性需求到來之前開始補充庫存。 據中國價格報告機構MySteel稱,在中國,頻繁的進口取消推高了國內價格,為棕櫚油期貨提供了「強勁」的支撐。 在美國,由於出口下降和產量穩定,紐約商品交易所(NYMEX)5月交割的乙醇期貨價格週四連續第三個交易日下跌0.52%,至每加侖1.90美元。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.